Plasma Mannose Associated Parameter Levels in Nondiabetic Coronary Artery Disease
Associations Between Serum Lipids and Mannose Levels in Coronary Artery Disease Among Nondiabetic Patients
1 other identifier
observational
240
1 country
2
Brief Summary
Aims: Nondiabetic patients have been studied to determine whether modest elevations in plasma mannose levels may be associated with a greater incidence of coronary artery disease (CAD). Methods: The plasma mannose, lipids (triglyceride, LDL, HDL, LDL, VLDL) and LDH levels were successfully will be evaluated with respect to subsequent coronary artery disease using records 120 nondiabetic patients and 120 healthy volunteers. CAD was identified from myocardial infarction and new diagnoses of angina. The associations between mannose levels and serum lipid parameters will be investigated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2018
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 10, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 10, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
May 15, 2020
CompletedFirst Submitted
Initial submission to the registry
May 7, 2021
CompletedFirst Posted
Study publicly available on registry
May 17, 2021
CompletedMay 17, 2021
May 1, 2021
2.3 years
May 7, 2021
May 11, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
Correlations between mannose levels and serum lipid parameters
This outcome aims to investigate the correlations between mannose levels and serum lipid parameters in patients who have body mass index under than 25 (kg/m\^2) and over than 25 kg/m\^2.
16 Months
Secondary Outcomes (2)
Correlations between mannose levels and infection parameters (CRP and others).
6 months
The effect of comorbidites on correlation between the serum mannose levels and serum lipid parameters and serum infecition parameters
6 months
Study Arms (2)
Coronary Artery Disease Group
Patients who underwent angiography at the Department of Cardiology and newly diagnosed as coronary artery disease and who weren't on statin treatment were included in the patient group.
Control Group
The control group consisted of healthy people with normal coronary arteries angiographically
Interventions
Mannose and lipid parameters (triglyceride, LDL, HDL, VLDL) will be analysed in blood samples by using ELISA method.
Eligibility Criteria
The patient and control groups will be initially informed about the study and obtained a written consent. Patients who underwent angiography at the Department of Cardiology and newly diagnosed as coronary artery disease and who weren't on statin treatment will be included in the patient group. The control group will be consisted of healthy people with normal coronary arteries angiographically. Patients with chronic renal failure, chronic liver disease, inflammatory disease, diabetes, insulin resistance, major metabolic or endocrine disease will also be excluded. For this purpose, age and sex matched 120 patients and 120 healthy volunteers will be admitted to study.
You may not qualify if:
- To be on statin treatment. To underwent angiography at the another department or university. Not to be newly diagnosed as coronary artery disease. To have a chronic renal failure, chronic liver disease, inflammatory disease, diabetes, insulin resistance, major metabolic or endocrine disease.
- For Control Group;
- To give written informed consent. To underwent angiography at the Pamukkale University Department of Cardiology. To have normal coronary angiography. Not to be on statin treatment.
- To be on statin treatment. To underwent angiography at the another department or university. To have a chronic renal failure, chronic liver disease, inflammatory disease, diabetes, insulin resistance, major metabolic or endocrine disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Aylin Koseler
Denizli, Outside of the US, 20070, Turkey (Türkiye)
Ramazan Sabirli
Kars, Outside of the US, 36000, Turkey (Türkiye)
Biospecimen
Blood samples will be used.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr.
Study Record Dates
First Submitted
May 7, 2021
First Posted
May 17, 2021
Study Start
January 10, 2018
Primary Completion
May 10, 2020
Study Completion
May 15, 2020
Last Updated
May 17, 2021
Record last verified: 2021-05